Edition:
India

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

6.90USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$6.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
123,376
52-wk High
$14.00
52-wk Low
$6.25

Chart for

About

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes... (more)

Overall

Beta: --
Market Cap(Mil.): $762.55
Shares Outstanding(Mil.): 73.68
Dividend: --
Yield (%): --

Financials

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER

05 Jan 2018

BRIEF-Aduro Biotech Expands Leading Intellectual Property Position In STING Field With Newly Issued Patent

* ADURO BIOTECH EXPANDS LEADING INTELLECTUAL PROPERTY POSITION IN STING FIELD WITH NEWLY ISSUED PATENT Source text for Eikon: Further company coverage:

20 Dec 2017

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

12 Dec 2017

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

10 Nov 2017

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

01 Nov 2017

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

27 Sep 2017

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

26 Sep 2017

BRIEF-HitGen and Aduro Enter Research Collaboration

* Entered into a multi-target multi-year collaboration with Aduro Biotech Inc

14 Aug 2017

BRIEF-Aduro Biotech files for resale of up to 25.41 mln shares of common stock by the selling stockholders‍​

* Aduro Biotech Inc files for resale of up to 25.41 million shares of co's common stock by the selling stockholders‍​ - sec filing Source text - http://bit.ly/2v0rE5d Further company coverage:

03 Aug 2017

BRIEF-Aduro Biotech files for mixed shelf of upto $300 mln

* Aduro Biotech Inc files for mixed shelf of upto $300 million - sec filing Source text - http://bit.ly/2w7SKYi Further company coverage:

03 Aug 2017

Earnings vs. Estimates